They did however note that the cohort of patients had low median basal values of thrombomodulin and thus concluded that this could perhaps suggest a thrombophilic state intrinsic to the MM disease process rather than then anti-myeloma therapy[44]. The gene discussed is THBD; the disease is Miyoshi myopathy.